Are you a Health Professional? Jump over to the doctors only platform. Click Here

Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To Drug Hypersensitivity

Print Friendly, PDF & Email

Study to evaluate the utility of prospective HLA-B*5701 screening on the incidence of abacavir hypersensitivity (ABC HSR) in 1800 previously ABC-naive adults with HIV-1 from Europe, Australia and other countries as applicable. The study has two (co-primary) objectives: i) to determine if screening for HLA-B*5701 prior to ABC-containing HAART results in a lower incidence of clinically-suspected HSR versus current standard of care (no genetic screening) and ii) to determine if screening for HLA-B*5701 prior to ABC-containing HAART, results in a significantly lower incidence of immunologically-confirmed HSR versus current standard of care (no genetic screening or patch testing).

Official Title

A Phase IV, Randomised, Multicentre, Double-Blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*5701) for Susceptibility to Abacavir Hypersensitivity


HIV Infections

Study Type


Study Design

Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment

Further Details

Primary Outcome Measures:

  • Incidence of clinically-suspected ABC HSR during the 6-week observation period.
  • Incidence of immunologically-confirmed ABC HSR.
  • The clinical diagnosis of which occurs over the 6-week observation period.

Secondary Outcome Measures:

  • Incidence of clinically-suspected ABC HSR in Caucasians and in different ethnic sub-groups.
  • Sensitivity and specificity, positive and negative predictive value of genetic screening for HLA-B*5701 for susceptibility of HSR.

Study Start

April 2006

Eligibility & Criteria

  • Ages Eligible for Study: 18 Years and above
  • Genders Eligible for Study: Both

Inclusion criteria:

  • Infected with documented HIV-1.
  • Subjects are Abacavir-naive (subjects can be antiretroviral therapy (ART)-naive or experienced).
  • All subjects must have a clinical need for treatment with Abacavir (ABC) or an ABC-containing product that precedes the decision to participate in the study.
  • If subjects are therapy naive they must meet the criteria for commencing HAART according to local guidelines.
  • ABC and ABC-containing products are not recommended during pregnancy. A female is eligible to enter and participate in the study if she is of:
    1. Non-child-bearing potential: women who are surgically sterile or post-menopausal, the latter indicated by history of no menses for a minimum of 1 year from the date of the screening visit.
    2. Child-bearing potential: women who provide a negative pregnancy test (beta-human chorionic gonadotrophin; beta-HCG) at Screening and who agree to one of the following methods of contraception (any contraception method must be used consistently and correctly, i.e., in accordance with both the approved product label and the instructions of a physician, during the study period and through epicutaneous patch testing where appropriate):
      • Complete abstinence from intercourse from 4 weeks prior to administration of the ABC-containing compound, throughout the study, and for at least 4 weeks after discontinuation of ABC or ABC-containing product.
      • Double barrier method (e.g., male condom/spermicide, male condom/diaphragm, diaphragm/spermicide). Hormonal contraceptives will not be considered sufficient forms of contraception for this study.
      • Any intrauterine device with published data showing that the expected failure rate is <1% per year.
      • Sterilisation (male partner of female subject).

Exclusion criteria:

  • Has previously received ABC-containing therapy.
  • Satisfies any contraindications or restrictions to ABC therapy as listed in the product labels. Treatment with ABC must be in line with the recommendations of the product label.
  • The subject or any of their healthcare providers is aware of the subjects HLA type.
  • Has undergone an allogeneic bone marrow transplant.
  • Has an active or acute CDC Clinical Category C event at screening. Treatment for the acute event must have been completed at least 30 days prior to Screening.
  • Current severe illness, including liver and renal failure, major organ allograft, malignancy requiring parenteral chemotherapy that can not be discontinued for the duration of the trial, or any other conditions which, in the opinion of the Investigator, would make the patient unsuitable for the study.
  • Any laboratory abnormality at Screening which, in the opinion of the Investigator, should preclude the subject’s participation in the study.
  • Pregnant women or women who are breastfeeding.
  • Any immunisation within 30 days prior to Day 1.
  • Subject is, in the opinion of the Investigator, unable to complete the 6 week Observation period and the EPT assessments as required.
  • Subject requires treatment with radiation therapy or cytotoxic chemotherapeutic agents within 28 days prior to Screening, or has an anticipated need for these agents within the study period.
  • Subject is enrolled in one or more investigational drug/vaccine protocols.
  • In France, an eligible subject is neither affiliated with nor a beneficiary of a social security category.
  • A subject will not be eligible for progression to Baseline (Day 1) if a positive result for HLA-B*5701 in those subjects randomised to the genetic screening arm.

Total Enrolment


Contact Details

  • Darlinghurst, 2010, Australia
  • Miami, 4220, Australia
  • Camperdown, 2050, Australia

Contact GlaxoSmithKline Australia for more information (refer to study ID numbers: CNA106030; PREDICT-1 or NCT00340080)

Print Friendly, PDF & Email


Posted On: 1 January, 2013
Modified On: 16 September, 2014


Created by: myVMC